BRAIN and NERVE－神経研究の進歩73巻1号

2021年01月発行

特集 Neuro-Oncology

免疫チェックポイント阻害薬による神経関連有害事象—新たな疾患概念の提唱

著者： 関守信¹ 鈴木重明¹

所属機関： ¹慶應義塾大学医学部神経内科

ページ範囲：P.35 - P.46

文献概要

免疫チェックポイント阻害薬（ICIs）による神経筋関連有害事象は稀ではあるものの時に重篤化することがあり，適切な診断，管理が重要である。髄膜脳炎，多発神経根炎，重症筋無力症，筋炎が特に重要で，これらが免疫関連有害事象として発症した場合，臨床像，経過，検査所見，治療が通常と異なることがあり，正しい理解が求められる。ICIsを中止し，ステロイド治療を行うことが推奨されており，反応性は良好である。

参考文献

1)Ishida Y, Agata Y, Shibahara K, Honjo T: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11: 3887-3895, 1992

2)Postow MA, Sidlow R, Hellmann MD: Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378: 158-168, 2018

3)Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, et al: Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl 4): iv119-iv142, 2017

4)Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, et al: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36: 1714-1768, 2018

5)Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, et al: Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 60: 210-225, 2016

6)Hottinger AF: Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 29: 806-812, 2016

7)Wick W, Hertenstein A, Platten M: Neurological sequelae of cancer immunotherapies and targeted therapies. Lancet Oncol 17: e529-e541, 2016［doi: 10.1016/s1470-2045(16)30571-x］

8)Blackmon JT, Viator TM, Conry RM: Central nervous system toxicities of anti-cancer immune checkpoint blockade. J Neurol Neuromed 1: 39-45, 2016

9)Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, et al: Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 73: 1-8, 2017

10)Spain L, Walls G, Julve M, O'Meara K, Schmid T, et al: Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol 28: 377-385, 2017

11)Eltobgy M, Oweira H, Petrausch U, Helbling D, Schmidt J, et al: Immune-related neurological toxicities among solid tumor patients treated with immune checkpoint inhibitors: a systematic review. Expert Rev Neurother 17: 725-736, 2017

12)Larkin J, Chmielowski B, Lao CD, Hodi FS, Sharfman W, et al: Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist 22: 709-718, 2017

13)Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, et al: Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol 74: 1216-1222, 2017

14)Yshii LM, Hohlfeld R, Liblau RS: Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. Nat Rev Neurol 13: 755-763, 2017

15)Spain L, Tippu Z, Larkin JM, Carr A, Turajlic S: How we treat neurological toxicity from immune checkpoint inhibitors. ESMO Open 4(Suppl 4): e000540, 2019［doi: 10.1136/esmoopen-2019-000540］

16)Spain L, Diem S, Larkin J: Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44: 51-60, 2016

17)Graus F, Dalmau J: Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol 16: 535-548, 2019

18)Sato K, Mano T, Iwata A, Toda T: Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database. J Neurooncol 145: 1-9, 2019

19)Dubey D, David WS, Reynolds KL, Chute DF, Clement NF, et al: Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum. Ann Neurol 87: 659-669, 2020

20)Suzuki S: Encephalitis as an immune-related adverse event. J Neurol Neurosurg Psychiatry 91: 680, 2020［doi: 10.1136/jnnp-2020-323212］

21)Chang H, Shin YW, Keam B, Kim M, Im SA, et al: HLA-B27 association of autoimmune encephalitis induced by PD-L1 inhibitor. Ann Clin Transl Neurol 7: 2243-2250, 2020［doi: 10.1002/acn3.51213］

T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nat Med 25: 1243-1250, 2019

23)Williams TJ, Benavides DR, Patrice KA, Dalmau JO, de Avila AL, et al: Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 73: 928-933, 2016

24)Vogrig A, Muniz-Castrillo S, Joubert B, Picard G, Rogemond V, et al: Central nervous system complications associated with immune checkpoint inhibitors. J Neurol Neurosurg Psychiatry 91: 772-778, 2020

25)Shah S, Dunn-Pirio A, Luedke M, Morgenlander J, Skeen M, et al: Nivolumab-induced autoimmune encephalitis in two patients with lung adenocarcinoma. Case Rep Neurol Med 2018: 2548528, 2018［doi: 10.1155/2018/2548528］

26)Kopecky J, Kubecek O, Geryk T, Slovackova B, Hoffmann P, et al: Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report. J Med Case Rep 12: 262, 2018［doi: 10.1186/s13256-018-1786-9］

27)Papadopoulos KP, Romero RS, Gonzalez G, Dix JE, Lowy I, et al: Anti-Hu-associated autoimmune limbic encephalitis in a patient with PD-1 inhibitor-responsive myxoid chondrosarcoma. Oncologist 23: 118-120, 2018

28)米延友希, 石島見佳子, 豊岡圭子, 藤村晴俊: 肺扁平上皮癌に対するpembrolizmab投与後に髄膜脳炎を来した1例. 臨床神経59: 105-108, 2019

29)Fujiwara S, Mimura N, Yoshimura H, Fujimoto D, Ito M, et al: Elevated adenosine deaminase levels in the cerebrospinal fluid in immune checkpoint inhibitor-induced autoimmune encephalitis. Intern Med 58: 2871-2874, 2019

30)Shibaki R, Murakami S, Oki K, Ohe Y: Nivolumab-induced autoimmune encephalitis in an anti-neuronal autoantibody-positive patient. Jpn J Clin Oncol 49: 793-794, 2019

31)Vogrig A, Fouret M, Joubert B, Picard G, Rogemond V, et al: Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm 6: e604, 2019［doi: 10.1212/NXI.0000000000000604］

32)Chang VA, Simpson DR, Daniels GA, Piccioni DE: Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation. J Immunother Cancer 6: 153, 2018［doi: 10.1186/s40425-018-0471-2］

33)Wilson R, Menassa DA, Davies AJ, Michael S, Hester J, et al: Seronegative antibody-mediated neurology after immune checkpoint inhibitors. Ann Clin Transl Neurol 5: 640-645, 2018

34)Shimada T, Hoshino Y, Tsunemi T, Hattori A, Nakagawa E, et al: Neuromyelitis optica spectrum disorder after treatment with pembrolizumab. Mult Scler Relat Disord 37: 101447, 2020［doi: 10.1016/j.msard.2019.101447］

35)Dubey D, David WS, Amato AA, Reynolds KL, Clement NF, et al: Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology 93: e1093-e1103, 2019［doi: 10.1212/WNL.0000000000008091］

36)de Maleissye MF, Nicolas G, Saiag P: Pembrolizumab-induced demyelinating polyradiculoneuropathy. N Engl J Med 375: 296-297, 2016

37)Wilgenhof S, Neyns B: Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann Oncol 22: 991-993, 2011

38)Okada K, Seki M, Yaguchi H, Sakuta K, Mukai T, et al: Polyradiculoneuropathy induced by immune checkpoint inhibitors: a case series and review of the literature. J Neurol Sep 9 2020［doi: 10.1007/s00415-020-10213-x］

39)Tanaka R, Maruyama H, Tomidokoro Y, Yanagiha K, Hirabayashi T, et al: Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barre syndrome: a case report. Jpn J Clin Oncol 46: 875-878, 2016

40)Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S: Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 16: 589-593, 2014

41)Patel AS, Snook RJ, Sehdev A: Chronic inflammatory demyelinating polyradiculoneuropathy secondary to immune checkpoint inhibitors in melanoma patients. Discov Med 28: 107-111, 2019

42)Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, et al: Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89: 1127-1134, 2017

43)Gonzalez NL, Puwanant A, Lu A, Marks SM, Zivkovic SA: Myasthenia triggered by immune checkpoint inhibitors: New case and literature review. Neuromuscul Disord 27: 266-268, 2017

44)Seki M, Uruha A, Ohnuki Y, Kamada S, Noda T, et al: Inflammatory myopathy associated with PD-1 inhibitors. J Autoimmun 100: 105-113, 2019

45)Johansen A, Christensen SJ, Scheie D, Hojgaard JLS, Kondziella D: Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review. Neurology 92: 663-674, 2019

46)Kadota H, Gono T, Shirai Y, Okazaki Y, Takeno M, et al: Immune checkpoint inhibitor-induced myositis: a case report and literature review. Curr Rheumatol Rep 21: 10, 2019［doi: 10.1007/s11926-019-0811-3］

47)Moreira A, Loquai C, Pfohler C, Kahler KC, Knauss S, et al: Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer 106: 12-23, 2019

48)Anquetil C, Salem JE, Lebrun-Vignes B, Johnson DB, Mammen AL, et al: Immune checkpoint inhibitor-associated myositis: expanding the spectrum of cardiac complications of the immunotherapy revolution. Circulation 138: 743-745, 2018

49)Kamo H, Hatano T, Kanai K, Aoki N, Kamiyama D, et al: Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report. BMC Neurol 19: 184, 2019［doi: 10.1186/s12883-019-1416-1］

50)Suzuki S, Utsugisawa K, Yoshikawa H, Motomura M, Matsubara S, et al: Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol 66: 1334-1338, 2009

51)Haddox CL, Shenoy N, Shah KK, Kao JC, Jain S, et al: Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm. Ann Oncol 28: 673-675, 2017

52)Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu SM, et al: Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer 4: 36, 2016［doi: 10.1186/s40425-016-0139-8］

53)Takamatsu K, Nakane S, Suzuki S, Kosaka T, Fukushima S, et al: Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia. Ann Clin Transl Neurol 5: 1421-1427, 2018

54)Kufukihara K, Watanabe Y, Inagaki T, Takamatsu K, Nakane S, et al: Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and/or myocarditis. Sci Rep 9: 5284, 2019［doi: 10.1038/s41598-019-41730-z］

55)Touat M, Maisonobe T, Knauss S, Ben Hadj Salem O, Hervier B, et al: Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology 91: e985-e994, 2018［doi: 10.1212/WNL.0000000000006124］

56)Vallet H, Gaillet A, Weiss N, Vanhaecke C, Saheb S, et al: Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma. Ann Oncol 27: 1352-1353, 2016

57)Leonard Louis S, Touat M, Maisonobe T, Allenbach Y, Benveniste O, et al: Clinical and histopathological features of immune-mediated necrotising and inflammatory myopathy in relation to treatment with immune checkpoint blockers (ICBs) in cancer patients. Neuromuscular Disorders 27: S151-S152, 1017

58)Noguchi E, Uruha A, Suzuki S, Hamanaka K, Ohnuki Y, et al: Skeletal muscle involvement in antisynthetase syndrome. JAMA Neurol 74: 992-999, 2017

59)Allenbach Y, Benveniste O, Goebel HH, Stenzel W: Integrated classification of inflammatory myopathies. Neuropathol Appl Neurobiol 43: 62-81, 2017

60)Suzuki S, Uruha A, Suzuki N, Nishino I: Integrated diagnosis project for inflammatory myopathies: an association between autoantibodies and muscle pathology. Autoimmun Rev 16: 693-700, 2017

61)Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, et al: Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 35: 785-792, 2017

62)Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, et al: Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol 4: 374-378, 2018